Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 2003-2004, 2005; 10.1373/clinchem.2005.053397
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heaney, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heaney, R. P.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:2003-2004.)
© 2005 American Association for Clinical Chemistry, Inc.


Editorials

Measuring What Isn’t There

Robert P. Heaney

Creighton University, 601 North 30th Street, Suite 4841, Omaha, NE 68131, Fax 402-280-4751, E-mail rheaney@creighton.edu

The first 300 words of the full text of this article appear below.

In the rush to develop "peaceful uses of the atom" in the years following testing of the H-bomb, much interesting work was done with radioactive calcium isotopes (45Ca and 47Ca). Perhaps most important was the finding that the relatively huge quantities of calcium contained in mature bone exchanged only negligibly with calcium either in extracellular fluid (ECF) or in immediately adjacent bone (1). This meant that tracer uptake by bone could be used as a direct measure of new bone mineralization. Although various complicated kinetic models were developed(2)(3), the mathematics were actually quite straightforward. The tracer content of a sample of bone calcium obtained days or weeks after an injection of a calcium isotope into an animal, divided by the average tracer concentration in ECF calcium, directly yields the mass of calcium deposited by bone formation during the interval between tracer injection and the time of the bone sampling.

What was missing from the picture was the ability to measure the other half of the bone remodeling/modeling process, i.e., bone resorption. How could one measure in a bone what was no longer there? Measuring the decrease in bone tracer content was not a feasible approach because the resorptive process removes mainly older bone, which contains little or no tracer. Despite this barrier and because so much of the interest in clinical bone biology was focused on bone resorption, there has for years been a search for a more "direct" quantification of the process. This quest was reinforced by the development of antiresorptive pharmacologic agents for the treatment of osteoporosis, as well as by the demonstration that resorption responds sensitively to environmental or physiologic signals, whereas bone formation tends to be relatively invariant over the short term (4).

Moreover, the investigational focus . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.